Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).
Nadia HarbeckFabio FrankeRafael Villanueva-VazquezYen-Shen LuDebu TripathyLouis ChowGovind K BabuYoung-Hyuck ImDavid ChandiwanaAnil GaurBrad LanoueKaren Rodriguez-LorencAditya BardiaPublished in: Therapeutic advances in medical oncology (2020)
HRQoL was maintained longer in patients who received ribociclib + ET versus placebo + ET. These data, combined with previously reported improvements in PFS and OS, support a strong clinical benefit-to-risk ratio with ribociclib-based treatment in pre- and perimenopausal patients with HR+/HER2- ABC.
Keyphrases
- phase iii
- double blind
- open label
- postmenopausal women
- clinical trial
- placebo controlled
- phase ii
- breast cancer risk
- electronic health record
- big data
- randomized controlled trial
- stem cells
- newly diagnosed
- bone marrow
- combination therapy
- mesenchymal stem cells
- young adults
- machine learning
- replacement therapy
- artificial intelligence